Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

[1]  E. Giné,et al.  Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network , 2022, Blood.

[2]  R. Flavin,et al.  p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma , 2022, Leukemia & lymphoma.

[3]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[4]  I. Flinn,et al.  Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. , 2022, The New England journal of medicine.

[5]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[6]  M. Dreyling,et al.  Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up , 2022, HemaSphere.

[7]  W. Klapper,et al.  Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network , 2021, Blood.

[8]  Michael L. Wang,et al.  Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials , 2021, Journal of Hematology & Oncology.

[9]  J. Cerhan,et al.  Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes , 2021, Blood advances.

[10]  S. Ferrero,et al.  Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. , 2021, The Lancet. Haematology.

[11]  S. Hohaus,et al.  Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study , 2020, Leukemia.

[12]  A. Kwiecińska,et al.  p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma , 2020, British journal of haematology.

[13]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[14]  W. Klapper,et al.  Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Rossi,et al.  KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study , 2019, Haematologica.

[16]  S. Hohaus,et al.  OUTCOMES IN FIRST RELAPSED‐REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE‐FIRST STUDY , 2019, Hematological Oncology.

[17]  Michael L. Wang,et al.  Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis , 2018, Haematologica.

[18]  K. Grønbæk,et al.  Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma , 2018, Haematologica.

[19]  A. Rosenwald,et al.  Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. , 2018, Blood.

[20]  J. W. Hansen,et al.  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. , 2017, Blood.

[21]  Michael L. Wang,et al.  Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies , 2017, British journal of haematology.

[22]  K. Grønbæk,et al.  Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. , 2016, Blood.

[23]  A. Rosenwald,et al.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Klapper,et al.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.

[25]  W. Klapper,et al.  High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. , 2015, Blood.

[26]  W. Klapper,et al.  Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.

[27]  E. Kimby,et al.  Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.

[28]  J. Šmardová,et al.  Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. , 2010, International journal of oncology.

[29]  Jeroen van der Laak,et al.  Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.

[30]  K. Vousden.  Outcomes of p53 activation - spoilt for choice , 2006, Journal of Cell Science.

[31]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[32]  K. Franssila,et al.  Ki‐67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma , 2002, European journal of haematology.

[33]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[34]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.